Articles Vol. 66 No. 4 25/07/2025

12. RELAPSE RATE WITHIN 12 MONTHS AND RELATED FACTORS IN PEDIATRIC PATIENTS WITH BASEDOW DISEASE AT CHILDREN'S HOSPITAL 2 ABSTRACT

Nguyen Thi Huyen1,2, Huynh Thi Vu Quynh3,4
1 Military Hospital 175
2 Bệnh viện quân y 175
3 The University of Medicine and Pharmacy at Ho Chi Minh City
4 Đại học y dược thành phố Hồ Chí Minh
Corresponding author: quynh.huynh@ump.edu
DOI: 10.52163/yhc.v66i4.2874
19 Views
16 Downloads
Keywords
Basedow disease Children's Hospital 2 Ho Chi Minh City.
Abstract

Objectives: To determine the relapse rate within 12 months and identify related factors in pediatric patients with Basedow disease at Children's Hospital 2.

Subjects and methods: A retrospective, descriptive case- series study was conducted on 34 pediatric patients who discontinued antithyroid therapy Methimazole (MMI) after completing treatment and were followed for at least 12 months or until relapse.

Results: The relapse rate was 38.2% within one year after stopping MMI therapy. Factors associated with relapse included delayed diagnosis, which increased the risk of relapse, and longer durations of MMI treatment, which reduced the relapse rate.

Conclusion: The relapse rate within 12 months is relatively common in pediatric Basedow patients. Extending the duration of MMI therapy to at least 18 months is essential to minimize the risk of relapse in children with Basedow disease.

References
[1]
Williamson Scott and Greene Stephen A, Incidence of thyrotoxicosis in childhood: a national population based study in the UK and Ireland. Clinical endocrinology, 2010. 72(3): p. 358-363. Google Scholar
[2]
Lane Laura C and Cheetham Tim, Graves’ disease: Developments in first-line antithyroid drugs in the young. Expert Review of Endocrinology & Metabolism, 2020. 15(2): p. 59-69. Google Scholar
[3]
Glaser Nicole S, Styne Dennis M, and Organization of Pediatric Endocrinologists of Northern California Collaborative Graves’ Disease Study Group, Predicting the likelihood of remission in children with Graves’ disease: a prospective, multicenter study. Pediatrics, 2008. 121(3): p. e481-e488. Google Scholar
[4]
Léger Juliane, et al., Graves' disease in children. Best practice & research Clinical endocrinology & metabolism, 2014. 28(2): p. 233-243. Google Scholar
[5]
Chiang Ya-Ting, et al., Long-term outcomes of Graves disease in children treated with anti-thyroid drugs. Pediatrics & Neonatology, 2020. 61(3): p. 311-317. Google Scholar
[6]
Hoàng Thị Thủy Yên and Nguyễn Thị Diễm Chi, Đặc điểm lâm sàng và cận lâm sàng bệnh Basedow trẻ em. 2021. Google Scholar
[7]
Nguyên Nguyễn Viết and Hương Ngô Thị Thu, Dịch tễ học lâm sàng, cận lâm sàng ở trẻ em bị bệnh Basedow tại Bệnh viện Đa khoa Xanh Pôn Hà Nội. Tạp chí Y học Việt Nam, 2022. 520(2). Google Scholar
[8]
Ross Douglas S, et al., 2016 American Thyroid Association guidelines for diagnosis and management of hyperthyroidism and other causes of thyrotoxicosis. Thyroid, 2016. 26(10): p. 1343-1421. Google Scholar
[9]
Minamitani Kanshi, et al., Guidelines for the treatment of childhood-onset Graves’ disease in Japan, 2016. Clinical Pediatric Endocrinology, 2017. 26(2): p. 29-62. Google Scholar
[10]
Nguyễn Bích Hoàng, Nhận xét kết quả và một số yếu tố ảnh hưởng đến điều trị bệnh cường giáp trạng bằng thuốc kháng giáp trạng tổng hợp ở trẻ em tại bệnh viện Nhi Trung Ương. 2005, Trường Đại học Y Hà Nội. Google Scholar
[11]
Wong Tsz Wai Catherine and Wong Man Yee Shirley, Remission in pediatric Graves’ disease treated with antithyroid drug and the risk factors associated with relapse. Annals of pediatric endocrinology & metabolism, 2022. 27(4): p. 308. Google Scholar
[12]
Nguyễn Minh Hùng, Nghiên cứu mối liên quan giữa tự kháng thể TRAb và một số thông số sinh học đến kết quả điều trị bệnh Basedow bằng Methimazole ở trẻ em. 2016, Trường Đại học Y Hà Nội. Google Scholar
[13]
Kaguelidou Florentia, et al., Predictors of autoimmune hyperthyroidism relapse in children after discontinuation of antithyroid drug treatment. The Journal of Clinical Endocrinology & Metabolism, 2008. 93(10): p. 3817-3826. Google Scholar